The investment, under the Translation Award programme, will help Nottingham-based RegenTec Ltd to develop commercial products in the rapidly-developing field of regenerative medicine. The company has perfected techniques which could greatly enhance the repair of bone defects and fractures.
RegenTec Ltd was created to build on the world-changing research carried out by scientists at The University of Nottingham, Britain’s ‘University of the Year’. With support from the East Midlands Development Agency, the company has invented a unique material that works with stem cells and biopharmaceuticals to stimulate the regeneration of tissue in patients.
When injected into the body the material forms a highly porous scaffold structure, which encourages new tissues to form.
The unique scaffold mechanism also assists the delivery of stem cells and drugs without compromising their effectiveness. This offers a substantial opportunity to deliver a cure to patients with bone, liver, heart or nerve tissue defects.
Professor Kevin Shakesheff, Chief Scientific Officer at RegenTec, and Director of The Centre for Biomolecular Sciences at The University of Nottingham, said: “The ability to inject these scaffold materials could significantly reduce the need for invasive surgery in tissue repair.
“It will mean that operation and rehabilitation times could come down significantly. After injection, the porous material we use gradually degrades, leaving behind only newly formed bone tissue.”
RegenTec has developed an extensive portfolio of patents and hopes that its injectable technology can reach clinics within three years. Its first product – Injectabone – will be used as a replacement for bone grafting, which can be beset by problems which include a short supply of host bone, chronic post-operative pain, and an increased risk of infection. Injectabone will be launched in the US and European markets for use by orthopaedic surgeons.
The material will then be adapted to help in treatment of many other diseases.
Dr Robin Quirk, Managing Director, said: “Regenerative medicine is a hugely exciting worldwide industry that promises to radically improve many aspects of clinical practice. We have a world-first technology that has a remarkable range of future uses.
“The Wellcome Trust Award is a substantial step forward in ensuring that the UK plays a major role in the commercial and clinical development of regenerative medicine.”
Dr Susan Huxtable, Director of Intellectual Property and Commercialisation at The University of Nottingham, said: “The Wellcome Trust Award is recognition of the hard work and creativity of a large team of scientists who have worked at the University of Nottingham and within Regentec over the past five years.
“They are pioneers in terms of their science, but also in ensuring that the expertise and knowledge honed in a research-intensive university can be translated into commercial enterprise, and make a dynamic contribution to well-being and economic growth. We have enjoyed a record year in attracting third party investment to our portfolio of spin-out companies.”
Emma Thorne | alfa
Ion treatments for cardiac arrhythmia — Non-invasive alternative to catheter-based surgery
20.01.2017 | GSI Helmholtzzentrum für Schwerionenforschung GmbH
Seeking structure with metagenome sequences
20.01.2017 | DOE/Joint Genome Institute
An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...
Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...
Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.
While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...
Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales
Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...
Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.
As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...
19.01.2017 | Event News
10.01.2017 | Event News
09.01.2017 | Event News
20.01.2017 | Awards Funding
20.01.2017 | Materials Sciences
20.01.2017 | Life Sciences